Analyst consensus rating
Moleculin Biotech Analyst Rating: Strong Buy
MBRX is rated Strong Buy by 3 analysts with a $18.33 target. As of 2026-08-23.
Direct answer
Moleculin Biotech's consensus rating is Strong Buy.
3 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $18.33.
Forecast evidence checked August 23, 2026.
Get free Moleculin Biotech email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $0.59
- Average price target
- $18.33
- High price target
- $31.00
- Low price target
- $2.00
- Low target gap
- +237.3%
- Target upside
- +2,991.6%
- High target gap
- +5,127.7%
- Target range width
- 4,890.4%
- Consensus rating
- Strong Buy
- Analysts
- 3
- Evidence date
- August 23, 2026
- Valid through
- August 30, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Moleculin Biotech?
Moleculin Biotech has a verified Strong Buy consensus. The same dataset has an average price target of $18.33.
How far are Moleculin Biotech's low and high targets from the recorded price?
The low target implies +237.3%, while the high target implies +5,127.7%.
How many analysts are included in Moleculin Biotech's consensus?
The verified consensus includes 3 analysts.
How is Moleculin Biotech's target upside or downside calculated?
The average target of $18.33 is divided by the recorded price of $0.59, then one is subtracted to produce +2,991.6%. This does not guarantee a future return.
When was Moleculin Biotech's analyst forecast verified?
The data was verified on 2026-08-23. The dataset is valid through 2026-08-30.